Assessment of the use of prompt gamma emission for proton therapy range verification by Styczynski, John R




SUBMITTED TO THE DEPARTMENT OF NUCLEAR SCIENCE AND ENGINEERING
IN PARTIAL FULFILLMENT OF THE REQUIREMENTS FOR THE DEGREES OF
MASTER OF SCIENCE IN NUCLEAR SCIENCE AND ENGINEERING
AND
BACHELOR OF SCIENCE IN NUCLEAR SCIENCE AND ENGINEERING
AT THE
MASSACHUSETTS INSTITUTE OF TECHNOLOGY
JUNE 2009









Department of Nuclear Science and Engineering
15 May 2009
Certified by
/7 Richard C. LanzaSenior Resc Scientist in Nuclear Science and Engineering, MIT
i h - .1 Thesis Supervisor
Certified by
Harald Paganetti





Prfeor in Nuclea ience and Engineering, MIT
Thesis Reader
? I /Jacquelyn C. Yanch
Professor in Nuclear Science and Engineering
Chair, Department Committee on Graduate Students
I

ASSESSMENT OF THE USE OF PROMPT GAMMA EMISSION FOR PROTON
THERAPY RANGE VERIFICATION
Submitted to the Department of Nuclear Science and Engineering on 15 May 2009 in Partial
Fulfillment of the Requirements for the Degrees of Master of Science in Nuclear Science and
Engineering and Bachelor of Science in Nuclear Science and Engineering
ABSTRACT
PURPOSE: Prompt gamma rays emitted from proton-nucleus interactions in tissue present a
promising non-invasive, in situ means of monitoring proton beam based radiotherapy. This study
investigates the fluence and energy distribution of prompt gamma rays emitted during proton
irradiation of phantoms. This information was used to develop a correlation between the
measured and calculated gamma emission and the proton beam range, which would allow
treatments to more effectively exploit the sharp distal falloff in the dose distributions of protons.
METHOD & MATERIALS: A model of a cylindrical Lucite phantom with a monoenergetic proton
beam and an annular array of ideal photon tallies arranged orthogonal to the beam was developed
using the Monte Carlo code MCNPX 2.6.0. Heterogeneous geometries were studied by inserting
metal implants into the Lucite phantom, and simulating a phantom composed of bone and lung
equivalent materials and polymethyl methacrylate.
RESULTS: Experimental and computational results indicated a correlation between gamma
emission and the proton depth-dose profile. Several peaks were evident in the calculated energy
spectrum and the 4.44 MeV emission from 12C was the most intense line having any apparent
correlation with the depth dose profile. Arbitrary energy binning of 4-5 MeV and 4-8 MeV was
performed on the Monte Carlo data; this binned data yielded a distinct emission peak 1cm
proximal to the Bragg peak. In all cases in the Lucite phantom the position of the Bragg peak's
80% distal falloff corresponded with the position of the 4-8MeV binned 50% distal falloff. The
4-5MeV binning strategy was successful with the heterogeneous phantom in which the proton
beam entered lung and stopped in bone. However, the density disparity between the bone and
lung equivalent materials rendered this technique unsuccessful for the heterogeneous phantom in
which the beam entered bone and stopped in lung. For this 1.4MeV binning was conducted,
assessing the 1.37 MeV characteristic gamma peak of 24Mg, which was only present in the lung
slab.
CONCLUSIONS: The results are promising and indicate the feasibility of prompt gamma emission
detection as a means of characterizing the proton beam range in situ. This study has established
the measurement and computational tools necessary to pursue the development of this
technique.
Thesis Supervisor: Richard C. Lanza
Title: Senior Research Scientist in Nuclear Science and Engineering
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The use of proton-beam based radiotherapy offers a number of advantages over more traditional
high energy photon sources, the most significant of which being the decreased integral dose
delivered to the patient while still achieving the necessary target dose. For most treatment sites,
protons offer greater tumor conformality with fewer beams than with photon techniques. The
unique depth-dose distribution of protons, which includes a Bragg peak after which nearly all
protons lose their kinetic energy, allows clinicians to either deliver a higher dose to the tumor,
increasing the probability of tumor control, or to reduce morbidity, or a combination of the two
options. Proton therapy is particularly appealing for the treatment of tumors in the brain, skull
base, and close to the spine, in which the target is close to a critical structure. By delivering less
integral dose to surrounding tissues, the use of proton therapy reduces the side effects (healthy
tissue necrosis, etc.) experienced as a result of dose delivered to healthy tissue. [Hall, 2006]
The advantages of proton beams as a source of therapeutic radiation were first realized in 1946
by Dr. Robert Wilson [Wilson, 1946]. Building off of Dr. Wilson's work, scientists in the 1960's
created the first proton therapy centers by modifying particle physics research facilities. The
development of hospital-based proton therapy centers began around 1990, and today 11 such
centers exist throughout the world, with 15 more proposed or under construction. Although
relatively esoteric compared to the ubiquity of traditional photon based radiotherapy centers,
protons are a rapidly growing tool in the arsenal against cancer.
While there is much to applaud about radiation therapy there remain important problems, one of
which this research seeks to address. Currently, there are no methods to predict or monitor the
proton depth-dose characteristics in situ. As a result, the clinical advantage afforded by the sharp
distal falloff in the depth dose profile of protons can not be fully exploited; an overestimate of
proton path length could cause an undershoot of the beam, resulting in an incomplete tumor
dosage and a decrease in tumor control probability, while an underestimate of the proton path
length would cause over-dosages of healthy tissues. Uncertainties, including CT artifacts, tumor
shrinkage, and setup variations, are taken into account by adding a safety margin to treatment
plans, which reduces the clinical advantage of protons. An accurate method of monitoring distal
edge falloff in administered fields would help maximize dose to the target, while minimizing dose
to healthy tissues distal to the tumor. In addition, precise knowledge of the distal edge falloff
would allow clinicians to use gantry angles in which the proton beam points directly at a critical
structure. Traditionally beam range uncertainties made such beam trajectories too risky to use on
patients, but with confirmation of the beam range, range uncertainty would no longer present a
problem.
One method of monitoring proton therapy delivery is by detecting the positron emitters ("C and
15O) created as the proton traverses the body. Coincident detection techniques used in a PET/CT
scan determine the position of origin of the detected annihilation photons. However, the
concentration of such positron emitters is relatively low (-lkBq/mL per Gy of absorbed dose),
and combined with the short half-lives of the positron emitters and the difficulties of monitoring
patients soon after treatment, there are still quite a few challenges to overcome before this
becomes a viable, efficient option for monitoring dose delivery. [Parodi, 2007a&b] [Knopf, 2008]
We aim to address the problem of proton dose delivery by assessing the feasibility of measuring
the gamma rays emitted during therapy via inelastic proton scattering, or a (p, p' y) reaction, from
carbon, oxygen, and nitrogen, among others. An induced prompt gamma activity from oxygen of
-3.5 MBq/mL from a 2 Gy treatment is expected - considerably larger than the PET signal.
Depending on mean proton energy, proton flux, and elemental composition, the rate of emission
will vary with depth in the target volume.
The impetus for interest in this technique was a study by Min et al., in which they were able to
successfully characterize the depth-dose profile of the proton beam in a water tank by measuring
the prompt gamma fluence at various points along the beam. [Min, 2006] Subsequent studies
have begun at Massachusetts General Hospital, as well as the MD Anderson Cancer Center.
2 RADIATION THERAPY: BACKGROUND AND SIGNIFICANCE
2.1 RADIATION THEORY AND INTERACTIONS
Radiation, defined as a microscopic wave or particle which transmits energy from one medium to
another, comes in a multitude of varieties, all with different sources and a unique set of physical
interactions with their environment. The massless photon, for example, is produced via the
acceleration of a charged particle (Bremsstrahlung, or X-rays) and the de-excitation of a nucleus
(y rays). The other commonly encountered form of neutral radiation is the neutron, a fermion
ejected from excited nuclei via fission or fusion. For charged particles, we have electrons, leptons
which are created from the decay of excited nuclei (f- particles) or the absorption of photons
(photoelectrons), as well as hadrons, heavy charged particles ranging from single protons to large
ions, most of which are produced during fission, fusion, or ionization. [Hall, 2006] [Turner, 2004]
As one may suspect, the variation of particle sizes, masses and charges leads to a variety of
interactions with matter. Photons, for example, transfer some or all of their energy to both orbital
electrons and nuclei, as well as spontaneously transform into an electron/positron pair (only
occurring if the photon's energy is greater than 1.022 MeV, the rest mass of the particle pair
created). Electrons collide with orbital electrons and decelerate in proximity to nuclei, while
neutrons collide with nuclei. Hadrons experience a variety of interactions with matter, mostly
colliding with orbital electrons, but they also collide with nuclei, both taking valence orbital
electrons from the atom and fissioning (in the case of heavy ions) as they traverse matter.
[Turner, 2004]
The variety of interactions that cause a particle to lose its kinetic energy result in different
transmission characteristics among the various flavors of particles. Photons, for example,
experience an evanescent (with respect to material thickness) transmission:
I = IoB(E)ej ()xdE (2.1)
where I is the beam intensity detected at the distal end of the beam in a material, Io is the initial
intensity of the beam (or intensity of the beam at the proximal edge of the beam in a material),
B(E) is the buildup factor, y is the attenuation coefficient, E is the photon energy, and x is the
material thickness. [Turner, 2004]
In contrast, protons exhibit a more complicated energy loss profile which must take into account
the ionization potential of the colliding electrons, the relativistic speed of the proton, and the
electron density of the target, all of which is taken into account with the Bethe Bloch formula:
dE 4Z Z z2  2me 2Tm
dx mec 2 PA 2 i 2C2TI2(1mfl2
(2.2)
Z vWhere p - is the electron density of the target, zP is the charge of the proton, f = -, and lis the
A c
ionization potential of the target. [Turner, 2004] Ultimately, this formula yields a transmission in
which the majority of the protons pass through a given thickness of material, experience a Bragg
peak (a peak of dose deposition) after which nearly all protons lose their kinetic energy. (Figure
2-1)
Figure 2-1: MCNPX simulation of a 150 MeV proton beam entering
and stopping in a Lucite phantom. Beam enters at bottom of figure
and traverses 15cm of Lucite before stopping. Note the beam
broadening as the protons traverse the phantom and the distinct
range of the beam. Each blue dot represents one collision between a
proton and the phantom material - as the proton beam traverses
more material and loses more energy, the density of collisions per
unit length increases, demonstrating the higher linear energy
transfer (LET) of proton beams at the Bragg peak.
Ionization and excitation of atoms are the primary means of energy loss for a high energy proton
traversing matter, with nuclear collisions becoming the more prevalent interaction as the proton
loses energy. As demonstrated by
4 MmQ = E (2.3)(M+ m) 2
where QMx is the maximum energy transfer between particles for an elastic collision, M and m
are the masses of the particles, and E is the energy of the incoming particle, the proton is only
able to transfer a small amount of energy to each electron with which it collides, yielding the
relatively straight paths observed in Figure 2-1.* If enough energy is supplied to the electron for it
to escape its atomic orbit, the electron becomes a 8 ray. Occasionally a proton will undergo
elastic scattering with a nucleus (as Rutherford observed with alpha particles), yielding a
substantial deflection from the proton's original trajectory, although this has an extremely low
probability. [Turner, 2004]
Inelastic scattering with nuclei is another possibility, and it causes the effects we aim to study.
During an inelastic collision, some of the energy imparted by the proton is absorbed by the
incident nucleus, with two likely possibilities. The first is that it knocks off a nucleon, say a
neutron, yielding a (p, p' n) reaction. The second possibility is that sufficient energy is not
imparted to knock off a nucleon, and instead a nucleon(s) is raised to a higher energy level. Both
possibilities create an unstable nucleus - the first restabilizes via P decay, the second via y decay
(which also competes with electron capture). [Turner, 2004]
2.2 RADIATION BIOLOGY
The variation in particle interactions inherently leads to a variety of biological effects as radiation
traverses an organism. For simplicity, we will only consider the effects to a cell's DNA, which can
be categorized as either direct effects, those which directly cleave one of more DNA strands, and
indirect effects, those which create reactive species (ie, H20 derived free radicals such as HOO,
the hydroxyl radical), which virulently attack DNA and other surrounding molecules in the cell
The mass of a proton more massive than an electron by a factor of 1836, which yields a maximum energy transfer
of 0.218% E.
nucleus. Free radicals are created with some frequency during natural cell processes (most
notably, the TCA cycle and ATP synthesis, a series of chemical reactions undertaken by all
aerobic organisms in order to produce usable forms of metabolic energy), and the body is
equipped with free radical scavengers to handle their presence (Vitamin E, among others). [Voet,
1995] If a free radical isn't scavenged, its attack on DNA may be reversed by the presence of an
SH compound, which will chemically absorb the radical. The presence of O2, however, increases
the susceptibility of a cell to indirect DNA attacks by binding with the free radical after it has
attacked the DNA; this peroxide radical can no longer be absorbed by an SH group, thus making
permanent the damage done to the DNA. As a result, hypoxic cells are less susceptible to the
indirect effects of radiation, while cells with a high concentration of 02 are more susceptible.
Photons and electrons, having little or no mass, primarily produce indirect effects, while hadrons
produce both indirect effects (creating 6 particles) and direct effects via collisions with nuclei in
DNA, breaking bonds and cleaving DNA strands. [Hall, 2006]
Given that indirect effects are more easily repaired than direct effects, indirect effects are less
biologically damaging per particle. As a result 1 Gray (1Gy=1J/kg deposited by radiation) of
photon radiation has a lower tissue lethality than 1Gy of hadrons, and the relative biological
effectiveness of hadrons, defined as the ratio of photon dose to test radiation dose to produce a
given biological endpoint, is approximately 1.1. [Hall, 2006] As a result, a conversion of photon
dose to proton equivalency, designated as Gy[RBE] (formerly known as GyE) is required for
treatment planning. [ICRU, 2008]
Not all cells are equally susceptible to radiation, nor do they all repair damage equally. Healthy
cells, on average, are better able to repair radiation damage than cancerous cells which have a
higher metabolic rate. As a result of this, and in attempting to reoxygenate the hypoxic regions
found in large tumor masses, treatments are typically performed in 20-30 fractions over 4-6
weeks. This allows the healthy cells to repair between fractions, and it allows the less susceptible
hypoxic cells acquire the vasculature once belonging to the outer, now necrotic, cancerous cells,
resulting in a more susceptible tumor core for the next treatment fraction.* [Hall, 2006]
Note that cancer cells will also repair between fractions, but their repair mechanisms are often slower than those of
healthy cells.
2.3 RADIATION THERAPY
The most prevalent form of radiation therapy involves the use of high energy X-rays. Photons
were the first radiation artificially produced (X-rays), their physics is well known, and the required
accelerators are relatively inexpensive to produce. Their abundance has caused all radiation
oncology training to focus on photon therapy, resulting in a significant library of literature on
treatment options and outcomes for various cancers. [Hall, 2006]
Photons do present some distinct limitations on efficacy and tissue sparing. As discussed above,
they primarily produce indirect effects to a cell's DNA. This, however, can be overcome by
overdosing a tumor volume; a sufficient dose will kill any cell regardless of susceptibility, and a
wealth of information exists on how much dose is required to kill a particular tissue type.
More limiting is the depth dose profile of a photon beam in tissue. As photons deposit energy in
tissue, maximum dose is delivered to the entry tissue, with an evanescent dose being delivered to
all tissues below the surface. As a result, all tissues are bathed in a dose, potentially severely
damaging healthy tissue. (Figure 2-2) This is not to say that photons can not be used to safely
treat tumor sites; current 3-D conformal and Intensity Modulated Radio-Therapy (IMRT)
techniques make use of multiple gantry angles and beam directions in order to keep the integral
dose relatively low to any given portion of healthy tissue while obtaining the required tumor dose.
S Photons h Bragg Peak
SPhotons]
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Figure 2-2: Depth dose profile of photons and protons in tissue [Bortfeld, HST.187]
Protons, however, posses a completely different, discrete dose profile, with a plateau and a 'Bragg
peak' of dose after which the proton beam stops, depositing no more energy in the tissue. As a
result, much greater tumor conformation with fewer beams, as well as greater healthy tissue
sparing can be achieved, resulting in more dose safely being delivered to the tumor while sparing
healthy tissue from lethal doses of radiation. Tumors of all types can be treated with protons and
the beam penumbra is smaller than photon penumbra for depths shallower than approximately
15cm. [Turner, 2006] [Bortfeld, HST.187] Because hadrons cause also direct radiation effects,
they are also more effective at treating tumors with a hypoxic core, as radical scavengers are
unable to assuage the damage done by their direct radiation effects.
Figure 2-3: Medulloblastoma treatment plans: photons (top) and protons (bottom) [Bortfeld, HST.187]
As can be seen in Figure 2-3, the photon treatment bathes a large percentage of the abdominal
cavity in doses exceeding 60% prescribed dose (red), while the proton treatment confines the
radiation dose to the treatment volume, resulting in lower morbidity due to the significantly lower
dose deposited in the tissues in the abdominal cavity. [Turner, 2006]
2.4 BRAGG PEAK: BOTH A BLESSING AND A CURSE
Proton therapy requires precise application in order to exploit its therapeutic advantage over
photons. If a situation arises in which the healthy tissue is inadvertently exposed to the Bragg
peak, healthy cell mutation and radiation induced necrosis and scar tissue may result. This is a
relative non-issue for photon therapy, where a 1cm lateral deviation results in a change of a few
per cent in dose deposition (-3% with a 6MV X-ray beam). [Gierga, 2009] In proton therapy,
however, the same 1cm lateral deviation may result in a 100% change in dosage, potentially
completely undershooting the target volume and depositing all dose in healthy tissue. [Hall, 2006]
[Turner, 2004] Two potential sources of this error are relatively easily corrected; physiologic
movement such as that of the lung or the heart (4-D treatment planning) and patient
misalignment (physically implanted markers and X-ray guided landmark alignment are used prior
to each fraction).
There are various sources of dose delivery error for which current techniques can not completely
compensate. CT 'star' artifacts, caused by fillings or other high-Z materials in the patient, lead to
an inaccurate calculation of tissue density, which is used directly by treatment planning algorithms
to determine the proton energies required for a specific depth penetration in tissue. If the
computed tissue density is higher than the actual value a higher proton energy will be selected by
the planning software, resulting in an overshoot of the proton beam. Therefore, dosimetrists
usually overwrite artifacts in CT images using estimated tissue densities, but this is an imperfect
process.
Another source of error is tumor shrinkage. Depending on the type of tumor, the volume may
decrease significantly over the course of treatment. (Figure 2-4) As healthy tissue moves into the
volume previously occupied by tumor, healthy tissue is exposed to the Bragg peak during
treatment. While one possible remedy may be to CT the patient intermittently during treatment,
the time and man power required to compare CT images and reevaluate treatment plans multiple
times during treatment is unrealistic. The number of patients that would benefit from such work
and increased radiation exposure is relatively small (because few tumors shrink to the degree that
there is significant overdosing of healthy tissues) compared to the number of patients receiving
proton therapy. [Mori, 2007]
Figure 2-4: Lung tumor CT (top) and proton treatment plan (bottom): initial scan, gross tumor volume
(GTV) 115cc (left), 5 weeks into treatment, GTV 39cc (right). Tumor volume hilighted in red. [Mori, 2007]
Yet another source of error that is frequently encountered in radiation therapy is patient
movement during treatment. The most extreme cases are encountered in thoracic cases (lung,
heart, etc.) However, new treatment planning methods and in situ monitoring devices (4D
treatment) have reduced the error associated with such movements. Patient movement from
treatment to treatment, which results from inconsistent patient positioning is more of a problem.
While this if often compensated for by using implanted seeds or pre-treatment X-rays, which use
landmarks for proper alignment, the methods are imperfect and misalignments can happen, as
demonstrated in Figure 2-5.
Figure 2-5: Prostate Treatment CT 08 Jan 2000 (left) and 11 Jan 2000 (right). Note the rotation of the
femoral head and the increased bone traversal length of the beam for 11 Jan. [Chen, 2000]
With such significant sources of error, it is difficult to ensure that the Bragg peak, which has
saved thousands of patients' lives and quality of life, does not inadvertently kill healthy tissue in a
few patients. Clinicians conservatively add a margin to the tumor volume to account for such
uncertainties - this both decreases the potential risk to the patient and reduces the advantages of
using a proton beam over more traditional high energy X-rays A quick, reliable and safe means of
imaging to ensure that the Bragg peak is being isolated solely to the tumor volume would greatly
help to ensure that treatments are being delivered as prescribed and maximize the potential
benefits afforded by proton physics.
2.5 CURRENT METHODS FOR IN VIVO PROTON THERAPY
MONITORING
2.5.1 POSITRON EMISSION TOMOGRAPHY
Positron Emission Tomography, or PET, has been around for decades and is a staple of the
nuclear medicine branch of diagnostic radiology. Antimatter, colloquially thought of as the stuff
of science fiction, provides the physical backbone of PET imaging. Positrons are created by
proton rich nuclei, which convert a proton (p) into a positron (P+), neutron (nU), and a neutrino
(v), plus kinetic energy for the neutrino and the positron.
p' *f +no+v (2.4)
This positron annihilates when in contact with an electron. Two annihilation photons result, each
with an energy of 51 lkeV traveling antiparallel to each other. These photons which are detected
during PET imaging. [Turner, 2004]
For nuclear medicine applications, a positron emitter is attached to a tracer molecule. Most
commonly, 18F is attached to glucose, resulting in florodeoxyglucose (FDG). Cancers, often
having a higher metabolic rate than surrounding healthy tissue, have a higher uptake of glucose,
which results in a brighter PET signal in the tumor volume. [Cho, 1993]
Once the FDG is injected and allowed to distribute throughout the body, the patient is placed in
a ring of photon detectors (scintillating crystals attached to photomultiplier tubes) which detect
the annihilation photons. [Knoll, 2000] Coincident detection techniques and reconstruction
algorithms are used to determine the origin of each photon pair; higher photon fluence
originating from a particular voxel indicates higher positron emitter concentration. [Cho, 1993]
Positron emitters are also created during proton therapy. As the proton traverses tissue, it mainly
loses energy via collisions with orbital electrons, knocking the electrons out of orbit and creating
6
-rays. Less frequently, a proton will collide with a nucleus, which may lead to a multitude of
events; if the proton is of sufficiently low energy it may be absorbed or it may scatter, taking with
it an orbital electron and becoming a hydrogen atom. Occasionally, upon collision with a nucleus,
the proton will knock off a neutron. If this happens to occur in carbon or oxygen (two
commonplace elements in the body) "50 and "C will result, both of which are proton rich,
unstable nuclei that undergo positron decay with halflives of approximately 2 minutes and 20
minutes, respectively. (Figure 2-6) The positrons created from these two isotopes behave
identically to the positrons used for PET imaging. As a result, it is possible to use a standard PET
scanning device to measure the concentration of 150 and 1"C in a particular volume. [Parodi,
2007b]
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Figure 2-6: Schematic of O0 production [Bortfeld, 2008]
There lies a correlation between the energy deposited per mass of tissue and the number of
positron emitters created; the PET signal is proportional to the proton fluence and the
probability of a proton-nucleus interaction which results in a positron emitter. [Parodi, 2007a]
Most importantly, the distal fall-off of the PET signal as a function of depth correlates
approximately with the dosimetric distal fall-off of the beam. The PET scan is completed
immediately after treatment, providing clinicians with immediate feedback as to the efficacy of
the treatment and the deposition of dose by the proton beam. (Figure 2-7)
However, PET verification is not without its drawbacks. The short halflives of the 150 and "C
require scanning immediately after treatment. After 20 minutes, the '~" signal is essentially zero,
and the "C signal has been reduced by a factor of 2. Biological factors affect the signal decay as
well - vasculature sweeps activated atoms away from their original irradiation site, ultimately









-100 50 0 50 1 -100 -60 0 50 100 -100 50 0 So 100
mm mm mm
Figure 2-7: Measured PET (left) Monte Carlo PET (middle) and treatment plan dose (right) for a patient
with pituitary adenoma receiving two orthogonal fields. [Parodi, 2007b]
The human body is not homogeneous. Tissues have varying composition, and different tissues
emit different signal intensities when subjected to the same dose. While this in and of itself is
relatively easily compensated for, when taken in conjunction with the biological decay and short-
lived isotopes upon which the technique relies, it is difficult to obtain a high SNR image that
accurately reproduces the dose profile in the patient. [Parodi, 2007a] The inability to provide a 1:1
correlation between the PET signal and dose has caused most current studies to use PET as a
range verification tool, instead of using it to recreate the dose profile, with clinically acceptable
levels of uncertainty. [Parodi, 2007b]
2.5.2 POST TREATMENT IRRADIATION MRI OF VERTEBRAL DISCs
Recent studies have shown that spinal proton treatment causes a characteristic pattern of fatty
conversion in the vertebral bone marrow that is visible on post treatment MRI scans. [Krejcarek,
2007] Groups have shown that a Tl-weighted hyperintensity of bone marrow from fatty
conversion is detectable by the end of radiation treatment and persists for at least 11
months.(Figure 2-8) [Blomlie, 1995] [Cavenagh, 1995] Promising work is being conducted in
developing a dose to post-treatment MRI signal intensity curve.
Figure 2-8: Treatment plan (left) Monte Carlo calculation (middle)
and MRI (right, blue line is planned 50% isodose line, red line is
estimated true 50% isodose line) of lower Lumbar
While the results are promising, the main drawback of this method is the timescale involved.
Current studies indicate that the observed TI hyperintensity initially occurs after treatment. As a
result, the clinician can not use this information to adjust the patient's treatment. While the
information provided is useful for quality assurance and future treatment planning practices
purposes, the damage has already been done to the patient at hand by the time the effect is
visible.
2.6 INSITU PROTON RANGE VERIFICATION ASSESSMENT VIA
PROMPT GAMMA DETECTION
While the aforementioned PET and MR methods have yielded some promising results and
warrant further research, they have inherent flaws and complications. The effect that biological
decay has on the PET signal makes it is difficult to obtain a high SNR representation of the beam
range with the PET method. And, while the MRI method provides wonderful data in hindsight,
it yields no data in the timeframe necessary for a clinician to change a patient's current treatment
plan.
Prompt gamma emission detection has the potential to provide meaningful proton range
verification in situ while avoiding some of the pitfalls discussed with other techniques. The
technique has the potential to provide instant data to the clinician during treatment, meaning that
the data can be analyzed by a clinician after any given fraction, and the remaining fractions can be
adjusted if needed. But information can potentially be gained regarding treatment before the first
fraction is delivered. The high gamma emission rate of approximately 3.5 MBq/mL/Gy,
considerably larger than the PET isotope production rate, may allow clinicians to deliver a micro-
fraction, which would mimic the actual treatment fractions while delivering a small dose to the
patient. This would allow clinicians to monitor the range and ensure compliance with the
treatment plan of the treatment beam before even one fraction was delivered to the patient.
While the data may not be as striking and vivid as the images produced via PET/CT and MRI,
the data are no less useful, and it is this simplicity and the high potential SNR offered by the high
activity rate that make prompt gamma emission detection such a potentially powerful tool.
3 PROMPT GAMMA: BACKGROUND AND INITIAL EXPERIMENTS
3.1 GAMMA DECAY
Gamma emission occurs when a nucleus decays from an excited state to a lower or ground state
and emits a photon of energy equal to the difference between the two nuclear states, and is
analogous to the emission of characteristic X-rays. [Krane, 1988] In the case of proton therapy,
the excited nuclear state results from inelastic scatter between the proton of energy Ep and a
nucleus in the material through which the proton is traversing. The proton collides inelastically
with the nucleus, scattering with an energy Ep', imparting an energy to the nucleus Enuceus=Ep-Ep' .
This excess energy in the nucleus causes one or more nucleons to enter an excited state. When
the(se) excited nucleon(s) return to their ground state, they emit a gamma with energy Ey= Enucleus.
This reaction can be described in shorthand as A(p, p' y)A. For example, one reaction that occurs
with carbon is 12C(p, p' 4.44MeV)12C, or
p+12C - p'+ 12*C
12* C 12C + Y4.44MeV
Given that nuclei have quantized energy states, such gamma emissions are quantized and
particular energies are characteristic of a given nucleus. Table 3-1 describes some of these
characteristic gamma rays, and Table 3-2 shows the composition of brain, muscle, water, and
polymethyl methacrylate (the latter two being common phantom materials).
Table 3-1: Summary of proton nuclear interactions with the elemental
constituents of tissue [Dyer, 1981] [Kiener, 1998]
Isotope Reactions Gamma-ray Energies (MeV)
12C 12C(p, ' y) 12C 12C(p,2p y) 11B 4.44
14 N 14 N(p, p' y)14N 1.64, 2.31, 5.11
160 160 (p, p' y) 160 2.74, 6.13, 6.92, 7.12
Table 3-2: Elemental composition (atom fraction) and density of brain, muscle,
phantom materials. [ICRU, 1989]
and representative
Density Elemental Atom Fraction
(g cm -3) H C N O
Brain 1.040 0.646 0.074 0.009 0.271
Muscle 1.014 0.633 0.074 0.015 0.278
Water 1.00 0.667 - - 0.333
PMMA 1.19 0.533 0.333 - 0.133
The probabilities of such reactions depend on the energy of the incident proton. The cross
section of 6O, for example, has a threshold of 8-10MeV, and a maximum of approximately 0.2
barns. (Figure 3-1)The cross section of "60 is representative of the other reactions listed in Table
3-1.
A typical proton therapy plan administers the proton beam at a rate of approximately 2Gy/min,
or 2.1xl10 14eV/cm 3/g. Dividing by the proton stopping power of approximately 40MeV/cm2/g
yields a nominal proton flux of 5.3x10 9/cm 2/s. The inelastic emission rate per unit volume can be
estimated as the product of the flux times the cross section (0.2x10-24cm) times the number
density of the particular nucleus (in this case, 160, 3.34x10 22/cm 3). This results in a gamma
emission rate of approximately 3.5 MBq/mL. As tissue composition changes and proton energy
decreases along the proton beam path, the rate of emission will vary with depth in target and the
emission fluence peak will be slightly proximal to or at the Bragg peak (depending on the initial
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Figure 3-1: Proton inelastic scattering cross section for two
different characteristic gamma ray lines (6.13MeV and 2.74MeV)
[Kiener, 1998]
3.2 INITIAL KOREAN STUDY
The first study conducted at the National Cancer Center of Korea by Chul-Hee Min et al. used a
100-200MeV proton pencil beam incident upon a water phantom. [Min, 2006] A CsI(T1)
scintillator was used to detect the gammas, and was collimated such that only gammas emitted
orthogonal to the central axis of the proton beam were registered. The collimator consisted of
two parts: a paraffin layer and a lead and B4C layer. The paraffin layer shielded the scintillator
from the high energy spallation neutrons emitted during therapy (which are mostly forward
oriented, but strong enough to compete with the photon signal at 900). This paraffin layer
moderated the neutrons, the B4C in the lead captured the neutrons by the B(n,y) reaction, and the
lead blocked these unwanted gammas. The lead layer also shielded from gammas that are not






Figure 3-2: Isometric and sectional views of the collimator setup [Min, 2006]
The prompt gamma emission rate correlated strongly with the proton depth dose profile, with a
gamma emission peak approximately at the location of the Bragg peak. (Figure 3-3) A significant
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Figure 3-3: Comparisons of the depth-dose distributions measured by the
ionization chamber (for proton dose profile) and the prompt gamma
scanner measurement at Ep=100, 150, and 200MeV. Note the slight dip in
photon signal slightly proximal to the Bragg peak. [Min, 2006]
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3.3 PRELIMINARY EXPERIMENTS AT MGH
Initial experiments were performed in one of three available therapy rooms at the Francis H.
Burr Proton Therapy Center at the Massachusetts General Hospital. In order to minimize the
high levels of background radiation that would normally be produced in the treatment room in
beam scattering devices used during therapy, measurements were performed using a pencil beam
(approximate diameter 5-6mm) with an energy of 150MeV and a beam intensity of 5nA. The
beam was incident upon a cylindrical Lucite quality assurance (QA) phantom with a diameter of
10.2cm and a length of 30cm. Gamma rays were measured at 90' to the central axis of the
incident beam using a cylindrical 2.5x5cm (diameter x length) Nal scintillator which was coupled
to a photomultiplier tube. The detector was collimated with lead bricks, with a wall 10 cm thick
and 80cm long, with a slit opening 5mm wide for the detector to view the emitted radiation.
(Figure 3-4)
Pulse height data were acquired on a commercial multi-channel analyzer (Canberra industries
DSA 1000) and were calibrated using the Compton peaks at 1173 and 1332 keV produced by a
60Co test source. The detector was positioned 52cm from the central axis of the proton beam and
was not shielded from room return scatter or radiation produced upstream in the beam line. The
assembly was scanned through the depth of the Bragg peak parallel to the beam direction. A
spectrum was acquired at each position for 100 MU of beam dose recorded by the dose
monitoring system routinely used during therapy. A monitor unit (MU) is defined as a certain
amount of charge collected in an ionization chamber and is a measure of the delivered dose in
radiation therapy.
Figure 3-4: Photograph of measurement setup. Nal scintillator
positioned orthogonal to the beamline behind shielding with a
5mm slit aperture (top), scanned along the beam path. Proton
beam enters from the right of the image into Lucite phantom
(yellow cylinder).
The measured spectrum yielded a gamma emission peak approximately 15mm proximal to the
Bragg Peak, with a relatively large gamma count distal to the Bragg Peak. The gammas distal to
the Bragg peak are attributed to recoil nuclei and neutrons causing activation beyond the proton
beam range. The local minima at approximately 18mm proximal to the Bragg Peak is still
unexplained (Figure 3-5), although a similar result was obtained by Min et alin the 225mm range
proton beam shown in Figure 3-3.
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Figure 3-5: Gamma emissions measured by Kent Riley and Peter Binns as a
function of distance along a Lucite cylinder for an incident 150MeV proton pencil
beam plotted with the calculated proton depth dose profile.
44.1
EXPERIMENTAL SIMULATION: GEANT vs MCNPX
GEANT 4.8.0
Initial simulations of the MGH experiment described in Section 3.3 were run using the GEANT
4.8.0 radiation transport code developed at CERN. GEANT was chosen because it is the most
ubiquitous radiation transport code used by medical physicists in the radiation oncology
department at MGH. As a result, a full setup of the proton beam treatment head has been
developed and benchmarked in GEANT, and Monte Carlo treatment planning for proton
therapy using GEANT is being developed. [Paganetti, 2008]. Initial runs consisted of the full
treatment head and Lucite phantom as well as the collimated NaI scintillator (Figure 4-1).
Particle-by-particle tracking was conducted on gammas created in the phantom, as well as those
that reached the Nal scintillator.
Figure 4-1: Schematic of experimental simulation. Lucite phantom
visible as white wireframe cylinder in the lower right. Collimating
blocks visible as purple and green wireframe boxes in the lower
right. Upstream proton therapy head components (beam degrader,
etc.) visible in the upper left.
However, initial simulations provided mixed results. The tally of gammas exiting the phantom
yielded the characteristic gammas of the materials comprising the phantom, as expected. (Figure
4-2)
le+6
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Figure 4-2: Spectrum of gammas leaving the Lucite phantom as
calculated by GEANT - Gamma peaks of H, C, and O
highlighted.
The gamma emission profile did not correlate with the proton depth dose profile as had the
previous MGH and Korean experiments. Even when energy gating was conducted to examine
only characteristic peaks, there was little distinction between the emission profile at and around
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Figure 4-3: Gamma emission profile plotted relative to the Bragg Peak position
A potential cause of this unexpected gamma emission profile was the angular distribution of the
emitted gammas. The angular distribution of emitted gammas from a proton beam incident on a
phantom (dictated by the angular differential cross section, do/dQ) should be relatively isotropic
(indicating that this is an l=0, or S-wave dominated reaction) or have a minima about 900. (Figure
4-4) [Kiener, 1998]
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Figure 4-4: Gamma emission angular distribution for Ep=14MeV (the
average energy of a proton in the Bragg peak of a 140 MeV beam) on
collodion (C 12H 16N 4 0 18 ) foils. [Kiener, 1998]
In contrast to this expected angular distribution, the gamma angular distribution varied wildly
over the proton beam path, with forward directed gammas at the Bragg peak, backward directed














Figure 4-5: Angular distribution of gammas exiting the phantom calculated with GEANT.
Initially it was thought that this may be a problem with the physics packages used with GEANT,
but subsequent examination showed that the most up to date physics packages were used for the
simulations, and that all angular binning definitions were geometrically correct. The issue is
currently under investigation by the Geant4 collaboration.
4.2 MCNPX v2.6.0 - ANGULAR DISTRIBUTION
Given this problem with GEANT, we decided to examine the angular distribution of gammas
with MCNPX, a radiation transport code developed by Los Alamos National Labs. [Pelowitz,
2008] However, MCNPX does not allow for particle-by-particle sampling as GEANT does, so a
method had to be developed in order to assess the angular distribution of photons leaving the
phantom (ie, we were not able to simply set up an if statement 'if the particle is a photon and
exits the phantom, note its trajectory's angle with respect to the proton beam central axis' as we
did with GEANT). The phantom was instead divided into regions of Lucite sandwiched between
very thin (0.0001cm) void areas with a photon importance of zero. (Figure 4-6)
..... .-.-.... . .I
p-beam
a b c d e f
Figure 4-6: Schematic of angular distribution geometry in MCNPX. The shaded regions (between surfaces
a&b, etc.) have a photon importance of zero. The proton importance throughout is one. White regions have
a photon importance of one. Photons' angular distribution with respect to the proton beam central axis are
tallied on each surface. For example, y 1 is tallied on surface c before being killed in the region between c
and d. y2 is tallied on surface g. y3 is tallied on surface d before being killed in the region between c and d.
Not to scale.
The resulting angular distribution calculated by MCNPX was closer to the expected angular
distribution described by Kiener et al with a symmetrical distribution about 90' and a local
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Figure 4-7: Angular distribution of photons exiting the Lucite phantom from MCNPX.
With these promising results, further benchmarking was undertaken to determine whether
MCNPX could be used to accurately simulate the physics of prompt gamma production from
proton beam therapy.
4.3 MCNPX - FURTHER BENCHMARKING
Two measures were used to determine whether the proton and photon physics simulated with
MCNPX were complete enough to simulate the prompt gammas emitted during proton therapy:
proton spectrum in phantom, spectrum of photons leaving the phantom.
4.3.1 PROTON ENERGY SPECTRUM
As the proton traverses a phantom, its energy spectrum should broaden, and at the Bragg peak
the average energy should be 10-15% of the original beam energy. At the entrance region, the
proton energy spectrum should be approximately that of the source.
0 20 40 60 80 00 120 140 16
Energy (MeV)
Figure 4-8: Energy spectrum of the proton beam calculated
by MCNPX at the entrance region (z=0 cm), plateau region
(z=5.5 cm), and Bragg peak (z=14.5 cm). Note the energy
broadening from a monoenergetic beam at the entrance
region to the broad energy range at the Bragg peak.
The proton energy spectrum calculated by MCNPX behaved as expected, with energy range
broadening as the beam loses energy and a peak energy of approximately 10-15% maximum
beam energy at the Bragg peak. (Figure 4-8)
4.3.2 GAMMA ENERGY SPECTRUM LEAVING PHANTOM
We demonstrated that the angular distribution of gammas concurs with published experimental
data [Kiener, 1998] (at least in the Bragg peak), but it is also necessary that we demonstrate that
the photon energy spectrum is correctly simulated by MCNP in order to thoroughly simulate the
experimental setup. The most important features that must be present are the characteristic peaks
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Figure 4-9: Energy spectrum of the gammas exiting the phantom calculated by MCNPX.
As before, a 150MeV proton beam was directed into a Lucite cylinder and the energy spectrum
of the exiting photons was recorded. The energy spectrum displayed the expected peaks -
4.44MeV (12C), 2.2MeV ('H), and 6.13 and 7.12MeV (160). (Figure 4-9) This spectrum, combined
with the correct angular distribution and the proton energy spectrum provided sufficient
evidence that MCNPX is able to adequately simulate the prompt gamma experiment.
5 HOMOGENEOUS PHANTOM IN MCNPX
5.1 EMULATING THE EXPERIMENTS CONDUCTED AT MGH
When simulating the experiment previously conducted at the Francis H. Burr Proton Therapy
Center by Peter Binns and Kent Riley, it was decided that the simulations would emulate ideal
conditions and equipment. As a result, only gammas created by the primary proton beam were
tracked. In order to obtain the highest signal possible (which ultimately reduces the error
associated with the tallies), an annular ring of sodium iodide (NaI) F4 tallies (flux averaged over
the cell) surrounded the Lucite QA phantom. (Figure 5-1) Phantom dimensions were identical to
the experimental QA phantom. The Nal tallies were arranged orthogonally to the incident proton
beam with an internal radius of 25.1cm, an external radius of 26.1cm, and a width of 1cm. In
order to obtain the proton depth dose profile, the QA phantom was divided into segments with a
length of 5mm along the proton beam path, each of which contained an F6 tally (energy
deposition averaged over a cell).
Figure 5-1: 3-D View of Lucite phantom and annular array of Nal
tallies (collimators not shown)
In order to ensure that the tallies registered only photons emitted orthogonal to the proton beam
central axis, thin (0.0001cm) ideal collimators were placed between each Nal ring, extending from
the phantom to the annular Nal. (Figure 5-1) Tallying was conducted from 0 - 20MeV with
increments of 100keV. A 147.5MeV monoenergetic proton pencil beam was delivered to the
Lucite phantom.* Approximately 103 million source particles (protons) were required to obtain






Figure 5-2: 2-D View of the phantom (center, red,
diameter=10.2cm), Nal tallies (sides, blue) and collimators
(lines extending from phantom to tallies). Proton beam
enters phantom from the bottom of the figure. Drawn to
scale.
The gamma emission profile yielded a total integral photon emission peak 2±0.5cm proximal to
the Bragg Peak, with plateau emissions ranging from 70%-90% of the peak. Spectrographic data
from the tallies revealed that the most abundant gamma emission near the Bragg peak was the
4.44MeV peak from 12C, likely due to the high percentage of carbon in Lucite. (Figure 5-3)
* 147.5 MeV proton beam emulates the 150MeV at-nozzle-entrance proton beam used during the experiments. The
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Figure 5-3: Energy spectrum of the gammas detected in the annular
tallies, 4-5MeV. Note that the fluence at the Bragg peak at 4.5MeV is
nearly a factor of 2 greater than other regions of the phantom.
Arbitrary integration about this energy (4-5MeV, as well as 4-8MeV, which was the energy range
examined during the initial experiments) was conducted. Both sets of binned data yielded an
emission peak at about 1±0.5cm proximal to the Bragg peak, with plateau emissions ranging
from 40%-70% and 30%-60% of the peak for the 4-8MeV and 4-5MeV gamma data,
respectively. (Figure 5-4)
This difference in peak position relative to the Bragg peak for the total and energy binned data is
to be expected - examining Figure 4-9 reveals that there is an abundance of low energy gammas
(large 400keV and 600keV peaks) particularly prominent in the plateau region, ultimately raising
the number of counts in the plateau region. 4-8MeV and 4-5MeV energy binning discounts these
low energy gammas, reducing the number of plateau counts without affecting the number of
Bragg peak counts.
The 4-5MeV data yielded the cleanest emission peak, with the highest peak to plateau gamma
fluence ratio. However, when compared to the total gamma fluence, narrowing the energy range
over which the fluence is integrated lowers the total number of counts received per Gy delivered
in the Bragg peak area. With this geometry, the total integral fluence to the 4-8MeV integrated
fluence ratio was approximately 1.9:1, whereas the total integral fluence to the 4-5MeV integrated
fluence ratio was approximately 3.4:1.
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Figure 5-4: Emission spectra as a function of depth in the phantom along
the beam path. 4-5MeV and 4-8MeV integrated and total integral fluences
plotted. Proton depth dose profile included, with the Bragg peak at a
depth of z=14.5cm.
While this is a relatively minor issue for these simulations which may simply run for longer
durations in order to achieve acceptable statistics, or even for an experiment, in which proton
beam time or current could be increased in order to obtain more gamma counts, it is a concern
for clinical scenarios in which a decreased fluence results in larger errors, and simply increasing
the dosage to obtain more counts is not an acceptable solution. However, the results indicate
that, while there is a significantly lower gamma fluence when energy binning is conducted, a 1cm 2
detector with 100% efficiency and 4-5MeV energy binning and 1Gy delivered at the Bragg peak
would yield a count of 613 photons and, according to Poisson statistics, an error of 4.1%. (Figure
5-5)
Dose delivered at the Bragg Peak was determined by placing a small cylindrical F6 tally (2cm x
1cm, radius x width) in the homogeneous Lucite phantom at z=14-15cm centered on the proton
beam central axis, resulting in a volume of n cm 3 with a mass of 3 .7 38g. Using the conversion
1MeV = 1.060217646x10- 3J, and 1Gy=1J/kg, the dose deposited in the volume per source
particle was determined. [Turner, 2004] Each proton source particle delivered 6.96x10-'OGy to the
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Figure 5-5: Fluence as a function of depth in phantom for a lcm2, 100%
efficient detector and 1Gy proton dose delivered at the Bragg peak. Depth
dose profile plotted for reference.
Computational results compare well to experimental emission peak results, which also yielded a
peak approximately 2-3cm proximal to the Bragg peak. Measured gamma emissions proximal and
distal to the emission peak, however, vary greatly from those computed by MCNPX, likely due to
the noise in the experiments. (Figure 5-6) Statistical uncertainty was relatively low (in most cases
<2%) for MCNPX calculations.
120
* Measured gamma emissions
100 - -.... Simulated gamma emissions (MCNPX) .






0 50 100 150
Depth (mm)
Figure 5-6: Gamma emissions measured as a function of distance
along Lucite cylinder for an incident 150MeV proton pencil beam
plotted together with an MCNPX calculated profile.
5.2 200MEV PROTON BEAM
As Figure 3-1suggests, the prompt gamma production cross section peaks at a proton energy of
approximately 10-11MeV. While this falls at or slightly distal to the Bragg peak for the 147.5MeV
proton beam used in our initial simulation, this is not the case for all energies.* In order to
examine the effect that higher energy beams have on the gamma emission spectra, the 147.5MeV
beam was replaced with a 200MeV proton beam. This higher energy beam will have a slightly
broader proton energy spectrum at the Bragg peak than the 147.5MeV, with an average energy of
approximately 20MeV.
The geometry used with the 147.5MeV proton beam was modified to account for the greater
penetration of the beam (the Bragg peak for the 200MeV beam was located at z=24.5cm,
whereas it was located at z=14.5 for the 147.5MeV beam). Material composition, beam
* As a rule of thumb, the average proton energy at the Bragg peak is equal to approximately 10% of the average
energy of the entrance beam.
i
characteristics (besides energy), physics settings, and detector/collimation schemes remained
unchanged.
Approximately 26 million source particles were required to obtain uncertainty of -2% for the
total gamma fluence detected in the Nal tallies. Run time was approximately 767 minutes.
The simulation yielded results similar the E,=147.5MeV simulation - the 4-5MeV and 4-8MeV
data displayed an emission peak approximately 1cm proximal to the Bragg peak, while the total
fluence emission peak was located 2cm proximal to the Bragg peak. (Figure 5-7) This curious
result is likely a result of the spatial resolution of our simulation geometry. Given that the Nal
tallies have a width of 1cm, the maximum achievable resolution is approximately 1cm. While the
average position of the 10-15MeV protons may be slightly closer to the Bragg peak from the
200MeV beam compared to the 147.5MeV beam, this movement is not on the order of 1cm, and
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Figure 5-7: Emission spectra as a function of depth in phantom along the beam
path for 200MeV proton beam.
path for 200MeV proton beam.
5.3 EFFECT OF SEED IMPLANT ON SIGNAL
Metal implants are not uncommon in radiation therapy patients. Quite often the spinal canal
needs Titanium screws for support after tumor mass has been removed surgically. The
implantation of a metal seed into the phantom was our first foray into phantom inhomogeneities.
Both titanium and gold seeds were simulated, with dimensions of 0.08cm x 0.3cm (diameter x
length), which were placed at z=5-5.3cm (the plateau region of the depth dose profile) directly
along the central axis of the proton beam. All other phantom and detector geometry and physics







Figure 5-8: 2-D view of phantom (diameter 10.2cm), Nal tallies,
collimators, and implanted Ti seed. Shown to scale.
Approximately 86 million source particles were required to obtain uncertainty of -2% for the
total gamma fluence detected in the Nal tallies. Run time was approximately 2735 minutes.
The energy spectrum at the entrance region and at the Bragg peak was nearly identical to the
spectrum of the phantom sans implanted seed. The energy spectrum at the seed position,
I lliZrmmT
~mp~--
however, displayed a significant increase in the number of low energy counts registered, with new
low energy peaks corresponding to the characteristic peaks of the seed materials. (Figure 5-9)
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Figure 5-9: Energy spectrum of the gammas detected in the annular
tallies. Ti seed implanted at z=5.0cm
This increased low energy gamma fluence resulted in a total emission peak at the location of the
implanted seed. Energy binning, however, yielded emission spectra not dissimilar to those seen in
Figure 5-4. Energy binning filtered the low energy gammas produced in the seed, resulting in an
emission profile similar to a Lucite phantom without an implanted seed.(Figure 5-10) While slight
local emission maxima can be observed at the seed location, the 4-5MeV and 4-8MeV data still
display a prominent peak 1cm proximal to the Bragg peak. This was the first time the benefits of
choosing an energy binning scheme such that the emission peak to plateau ratio is maximized
was fully realized. This result suggests that, with energy binning, the presence of a metal implant
should not prevent this technique from being used on a patient. It does not, however, suggest
that a metal implant could be used in conjunction with the prompt gamma detection technique in
order to better assess the proton beam range.
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Figure 5-10: Emission spectra as a function of depth in the phantom
along the beam path. Ti seed implanted at z=5.0cm.
5.4 COMMONALITIES
The implanted seed geometry made apparent that energy binning with respect to gamma peaks
that are preferentially abundant at the Bragg peak can help to filter the signal and obtain a clear
emission peak near the Bragg peak.
Interpolation between data points revealed that in all Lucite phantom simulations the position of
the 50% distal falloff in photon intensity for the 4-8MeV data correspond with the position of
the 80% distal falloff of the Bragg peak. While the poor (1cm) spatial resolution of the detector
geometry prevents us from concluding that this relationship always exists, it is an intriguing
correlation which should be studied further and may prove useful in clinical setups.
6 HETEROGENEOUS PHANTOM IN MCNPX
6.1 DESCRIPTION OF HETEROGENEOUS PHANTOM
In order to assess the possible effect that tissue inhomogeneities might have on the gamma
signal, a heterogeneous phantom was simulated which consisted of bone and lung equivalent
materials and poly-methyl methacrylate (PMMA). The slabs were arranged to form air-lung, air-
bone, and lung-bone interfaces which were positioned parallel or at a 6' angle relative to the
PMMA slabs. The phantom also contained an arrangement of six metal implants, two of which
were authentic dental gold implants, and the remaining four were composed of a tin lead alloy.
This particular phantom was chosen because it was developed and constructed in house at MGH
for a proton/PET study, and is readily available for experiments. [Knopf, 2008]
Table 6-1: Elemental composition (fraction by weight) and density of
the PMMA and tissue equivelent materials. [Knopf, 2008]
Medium H (%) C (%) N (%) O (%) Mg (%) Cl (%) Si (%) Ca (%) p (g/cm)
PMMA 8.05 59.99 - 31.96 - - - - 1.18
Bone
Eq. 3.41 31.41 1.84 36.5 - 0.04 - 26.81 1.82
Lung
Eq. 8.46 59.38 1.96 18.14 11.19 0.10 0.78 - 0.30
Figure 6-1: Drawing of MGH's in-house designed heterogeneous phantom
Figure 6-2: Picture of the heterogeneous phantom in one of the proton
beam gantries at the Francis H. Burr Proton Therapy Center. [Knopf,
2008]
The tallying scheme used was similar to that used on the Lucite phantom. An annular ring of Nal
F4 fluence tallies surrounded the heterogeneous phantom, which were arranged orthogonal to
the proton beam central axis with an internal radius of 25.1cm, and external radius of 26.1cm,
and a width of 1cm. In order to obtain the depth dose profile of the proton beam in the
phantom, sections of the phantom which ran along the proton beam path were divided into 2cm
x 0.5cm (diameter x length) cylinders, each of which contained an F6 energy deposition tally.
(Figure 6-3)
rlgure 0-i: i-i) view ot neterogeneous pnantom ana annular array ot
tallies (collimators not shown). Note the small round section of the
phantom - the portion sectioned off to obtain the proton depth dose
profile.
Similar to the Lucite phantom simulations, thin (0.0001cm) ideal collimators were placed between
each Nal tally in order to ensure that only photons emitted orthogonal to the proton beam were
tallied. Given that the heterogeneous phantom is not cylindrically symmetric about the proton
beam central axis, these collimators could not extend from the phantom to the tallies. Instead,
they came as close as possible to the phantom, touching the phantom's corners, with an internal
radius of 16cm and an external radius of 25.1cm. Note that the annular tallies are not centered
about the proton beam's central axis, but the center of the phantom. While this is not the ideal
scenario, this geometry provided the maximum collimator length, and still was able to effectively





Figure 6-4: 2-D View of the heterogeneous phantom in which the
beam enters lung (yellow) and stops in bone (blue) equivalent
materials. Phantom also includes PMMA (red), surrounded by NaI
tallies (green) and collimators (lines extending from the NaI). Note
the segments used to determine the depth dose profile of the proton
beam.
While there were a number of available scenarios that could be examined with this phantom, only
two were simulated: the proton beam entering bone and stopping in lung equivalent material, and
the proton beam entering lung and stopping in bone equivalent material. This was chosen over
also including PMMA (which is often used as a tissue equivalent material for radiological studies)
because the bone and lung equivalent materials represent the highest and lowest density materials,
respectively, providing the greatest contrast between two materials. The implanted seeds were not
used because the effect that an implanted seed has on the gamma signal was already examined
with the Lucite phantom, and the main goal was to study the effect that inhomogeneities in tissue
composition have on the gamma signal.
6.2 PROTON BEAM: LUNG - BONE
The first simulation conducted used a heterogeneous phantom geometry in which the proton
beam passed through 7.6cm of lung equivalent material before stopping in bone equivalent
material. The Bragg peak occurred at zzl7cm, with an approximate range of 10.4cm in the bone
equivalent material. A 147.5MeV proton beam was delivered. Approximately 5 million source
particles were required to obtain uncertainty of <10% for the total gamma fluence detected in the
Nal tallies. Run time was approximately 255 minutes.
Spectrographic data from the tallies revealed that, once again, the most abundant gamma
emission peak near the Bragg peak was the 4.44MeV peak from 12C. It should be noted that there
were other peaks which were more abundant at the Bragg peak than in other areas along the
depth dose profile in the phantom, including gamma energies of 2.2, 2.9, and 3.8MeV. While the
photon count at these energies was significantly higher than at the same energy for other regions
of the phantom, these peaks were isolated. The 4-5MeV range not only included the prominent
4.44MeV peak, but was also the largest range over which the photon counts at the Bragg peak
was consistently higher than at other areas of the phantom. As a result, integration of the 4-
5MeV data was conducted. (Figure 6-5)
4.5E-07
-- Plateau Region, Lung










0 1 2 3 4 5 6
Photon Energy (MeV)
Figure 6-5: Energy spectrum of the gammas detected in the annular tallies, 0-6MeV.
The normalized data revealed that both the total gamma fluence tallies and the 4-5MeV fluence
yielded emission peaks approximately 1.5±0.5cm proximal to the Bragg peak. Figure 6-6 reveals
that the fluence in the lung region was significantly lower than in the bone region, mostly due to
the difference in density between the bone and lung equivalent materials (bone equivalent
material is a factor of 6.1 more dense than lung equivalent material). The 4.5MeV data had a
higher peak to plateau ratio, displaying a more distinct peak.
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Figure 6-6: Normalized emission spectra as a function of depth in the
phantom along the beam path. Note the lung and bone equivalent
regions (z=0-7.6cm and z>7.6, respectively)
As may be assumed by the higher error bars in the 4-5MeV data when compared to the total
fluence data, the 4-5MeV data received fewer counts. Just as with the Lucite phantom, narrowing
the range over which the fluence is integrated lowers the total number of counts received per Gy
delivered to the Bragg peak area. The total fluence tallies recorded approximately 10 times more
counts than the 4-5MeV tallies. (Figure 6-7)
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Figure 6-7: Fluence as a function of depth in phantom for a 1cm 2,
100% efficient detector and 1Gy proton dose delivered at Bragg peak.
Depth dose profile plotted for reference.
While the relatively low number of counts may present a problem for clinical implementation it
was not an issue for these simulations, and the data show that, for the given geometry, a peak can
be measured in the gamma emission profile which correlates with (but is not at the location of)
the Bragg peak.
6.3 PROTON BEAM: BONE - LUNG
The second simulation conducted using a heterogeneous phantom switched the positions of the
lung and bone equivalent slabs. In this case the proton beam passed through 7.6cm of bone
equivalent material before stopping in lung equivalent material. (Figure 6-8) The Bragg peak
occurred at z=17.5+0.25cm, with an approximate range of 11.5cm in the lung equivalent
material. In order to use the same detector geometry used in the Lung-Bone study, the proton
beam energy was reduced to 140MeV (otherwise the proton beam would have passed beyond the
final Nal tally). Approximately 41 million source particles were required to obtain uncertainty of
-2% for the total gamma fluence detected in the NaI tallies. Run time was approximately 1202
minutes.
p+ beam
Figure 6-8: 2-D View of the heterogeneous phantom in which the
proton beam enters bone (blue) and stops in lung (yellow) equivalent
materials.
Spectrographic data revealed that the integral photon flux from bone equivalent material was
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Figure 6-9: Energy spectrum of the gammas detected in the annular tallies, 0-8MeV
As a result, the strategy used prior (finding a peak, namely 4.44MeV, which is preferentially
higher in the Bragg peak region than in all other locations) would not work, as there is no energy
at which the Bragg peak region emits a higher gamma fluence than any other region in the
phantom. Instead, only the emission and energy spectrum in the lung equivalent material region
were considered.
Upon closer inspection, it was revealed that there was one peak (1.4MeV) at which a slightly
higher fluence is detected in the Bragg peak region than in the rest of the lung equivalent slab.
This is likely the 1.37MeV line from 24Mg, which makes up 11.19% (by weight) of the lung
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Figure 6-10: Energy spectrum of the gammas detected in the annular
tallies, 1-2MeV. Note the slight difference between the plateau and
Bragg peak regions at 1.4MeV.
The data normalized to the highest fluence in the entire phantom displayed global maxima for
both the total fluence and 1.4MeV fluence, with the 1.4MeV data also displaying a local maxima
1±0.5cm proximal to the Bragg peak. When renormalized to take into account only fluence
emitted from the lung equivalent slab, this maxima 1±+0.5cm proximal to the Bragg peak becomes
more prominent. (Figure 6-11)
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Figure 6-11: Normalized emission spectra as a function of depth in the phantom along the beam path. Top:
Normalized to the peak fluence from all points in the phantom. Bottom: Normalized only to lung region.
This binning strategy suggests that understanding the composition of the tissue/material in which
the proton beam stops is critical, especially when there is a great difference in density between the
two materials. In such a case, one must take into account the density of a particular isotope of
interest.
For example, the lung equivalent material had a greater percentage of carbon, by weight, than the
bone equivalent material in the heterogeneous phantom. However, when one takes the density of
each material into account, the density of carbon in the lung equivalent material is 0.17814g/cm3,
while the carbon density in the bone equivalent material is 0.571622g/cm3 , a difference of a
factor of 3. As a result, the 4.44MeV peak was more abundant in the bone slab.*
In this case, it was necessary to perform energy binning in the Bragg peak area, suggesting that
particularly inhomogeneous geometries in which it is uncertain in what material the proton beam
stops, require a more advanced filtering method than those examined for this study. However,
this study suggests that it is possible to determine the range of a proton beam based on the
prompt gamma emission profile, provided the material in which the beam stops is known.
While this presents a difficulty in implementing this technique clinically, it is not impossible.
Algorithms are already in use which correlate each voxel in a CT to a particular tissue type based
on the Hounsfield reading in that area. With this technique, it could be determined what types of
tissues a proton beam will traverse for a given gantry angle, allowing physicists to predict the
observed gammas and conduct energy binning accordingly.
* Its abundance is not greater by a factor of 3 with respect to the abundance in the lung equivalent material because
the higher energy proton beam in the bone equivalent material has a smaller 4.44MeV gamma cross section than
does the lower energy proton beam in the lung equivalent material. Had the 4.44MeV gamma production cross
section not been a function of proton energy, the 4.44MeV gamma emission from the bone would have been
3.203(=0.571622g/cc/0.17814g/cc) times higher than the emission from the lung equivalent material.
7 FUTURE WORK
7.1 EXPERIMENTAL
The first round of experiments conducted at the Francis H Burr Proton Therapy Center were
little more than an attempt to reproduce the results published by Min, et al. The results of those
experiments do reveal a correlation between the gamma emission profile and the depth dose
profile of the proton beam, but they also include some anomalies, including an unexpected
fluence dip approximately 10cm proximal to the Bragg peak, and a significant photon fluence
distal to the Bragg peak. Further experiments must be conducted in order to determine the cause
of these anomalies, and how they may affect the overall viability of prompt gamma emission
detection as a means of proton beam range verification.
In addition, while the simulations described above have provided a wealth of information as to
the potential signals we may receive from different types of geometry and material compositions,
all of this must be verified experimentally. Our MCNPX simulations represent an idealized world
in which detectors are 100% efficient, collimators are thin and stop any extraneous particle that
collides into them, and in order to obtain acceptable statistics we need only dedicate more
computer time to the simulation. It needs to be determined whether the energy binning
techniques provide a large enough signal for a clinically relevant number of monitor units, or
whether other means of signal filtration may provide a greater SNR.
One potential means of filtering may be to examine angled collimators, examining gammas
emitted at some angle 0 (where 0:90o, as that scenario has already been examined). Recall from
Figure 4-4 that the gamma emittance differential cross section reaches a maximum at 300-40o.
Using an angle at which more gammas are emitted would lead to a greater number of counts
registered in a detector, ultimately yielding a higher SNR.
7.2 COMPUTATIONAL
While the importance of experimental validation is crucial to determining whether the idealized
MCNPX results correspond to meaningful real-world results, there is an abundance of future
simulations which should be conducted to aid experimental work and examine clinical settings.
MCNPX could be used to optimize the experimental setup, by examining various collimation
widths, collimation lengths, dimensions of shielding, distance of detectors from phantom,
distance between detectors, collimator angle, etc. This is a task more easily simulated than
experimentally tested, and would likely reduce the number of experiments necessary to obtain
meaningful experimental validation and move to a more clinical focus for this study. Simulations
should also be undertaken which have a finer spatial resolution around the position of the
maximum gamma emission in order to more accurately correlate the emission peak with the
Bragg peak.
In addition, simulations could be conducted which examine a more clinically relevant target
phantom. Instead of examining slabs of tissue equivalent materials, we could instead examine
more lifelike geometries. Numerous options are available, from the relatively simplistic Oak
Ridge National Laboratory mathematical model phantom, to the more complex voxelized VIP
Man developed at the Renssealer Polytechnic Institute. [Guatelli, 2005] [Jiang, 2005] (Figure 7-1)
Simulations could be developed which mimic an actual treatments, resulting in a spectrum
representative of what we should expect when we scan a patient.
Figure 7-1: ORNL female phantom (left) and VIP voxelized phantom (right)
Work should also continue to determine the source of the problems with our implementation of
GEANT4.8.0 (or of GEANT itself), and why it is currently failing to accurately represent the
correct angular distribution of the emitted gammas. Current collaboration with Tatsumi Koi at
the Stanford Linear Accelerator Laboratory is promising. Recent work has shown that the use of
the GetMomentumDirection function (as opposed to the geometrical means we had used
before, see Appendix B) for photon tracking has yielded gamma angular distributions which are
consistent with published data and MCNPX simulations.
If we are able to resolve this problem, we would be able implement an actual treatment beam and
real patient CTs, as the programs have already been developed which incorporate the patient CT
information and treatment plan into GEANT. Ultimately, this may allow us to scan the gammas
emitted from a patient and, using that patient's CTs and treatment plan input into GEANT,
simulate the gamma emittance as well. Such studies would also help develop a quantitative




Prompt gamma emission detection is a promising means of range verification during proton
therapy. It is the only current method that has the potential to provide in situ range information
to clinicians and physicist without the complication of biological decay. While this technique is
still in its infancy, we and others have shown that there is a correlation between the gamma
emittance profile along the proton beam path and the proton depth dose profile. While
inhomogeneities in the target geometry complicate matters, methods of filtering (namely,
integrating fluence over a set photon energy range) greatly improves results.
There is still a great deal of work to be done before this becomes a clinically viable tool. Our
studies have merely demonstrated a qualitative correlation between gamma emission profile and
depth dose profile. Further studies must be conducted to develop a quantitative correlation.
Experiments must verify that the simulated results are reproducible in a real-world setting, and
further benchmarking must be conducted before the simulations can provide quantitative data
that will be used for patient treatment assessment. In addition to the work at MGH, centers
around the world are beginning to realize the potential of this technique, with significant
contributions being made by Min and Kang et al at the National Cancer Center of Korea, and
Polf et alat the MD Anderson Cancer Center. [Min, 2006] [Kang, 2009] [Polf, 2009]
While tackling these issues is no simple task, the potential benefits are well worth the work.
Should the potential of this technique come to fruition to provide range verification during
proton therapy, clinicians could reduce treatment planning margins, and errors that affect the
proton beam range could be detected and corrected. If used clinically, this technique would spare
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APPENDIX A MONTE CARLO TECHNIQUES AND MCNP
Monte Carlo techniques use random numbers to simulate radiation transport through a given
environment. An input deck is defined by the user and includes the geometry of the problem, the
source position(s), spread, vector, etc., types and positions of tallies to be included, the cross
sections to be referenced, and what types of physics are to be included (what particles are
tracked, energy cutoffs, types of interactions to be considered etc.). The probability of a particle
interacting over a given path distance is defined by the cross section, and by using random
numbers between 0 and 1 and choosing the path length from the cumulative probability
distribution, a sampling of the path lengths between collisions for a given particle are obtained.
The same procedure is used to determine the type of interaction that may take place during a
collision and the resulting particle(s) trajectory(s). [Yip, 2006]
Tallies use various means (time of flight, etc.) to determine the number of particles passing
through a given cell or across a given surface, or to determine the amount of energy deposited in
a given cell. Tallies are segmented by particle energy, energy deposited, particle angle, or time.
The results are normalized to produce a quantity (particle fluence, MeV deposited, etc.) per
source particle.
MCNP repeats this process for a given number of source particles and for each particle created
via a collision or Bremsstrahlung (provided the new particle does not have an importance of zero,
in which case it is not considered by MCNP). The results are summed and averaged, and error is
estimated in the tallies based on the tally deviations. [Johnson, 2006]
APPENDIX B MCNPX ERROR: ENERGY BINNING
Given that MCNPX outputs tallies in a quantity-per-source-particle basis, one can not simply use
Poisson statistics to determine the error associated with a given sample. For example, the Nal
tallies outputted photon fluences from 0-20MeV with increments of 100keV (0.1MeV). However,
in certain cases we wanted to only sample a small portion of this output, most often 4-5MeV. In
order to obtain the total fluence, it was possible to simply sum the results for each energy in the
desired range. Error, however, could not simply be summed. To complicate matters further,
MCNP error is given as a relative error, where
MCNP relative error (RE) = % Error
Std. Deviation or
MCNP relative error = Std. Deviation
Mean p
We therefore obtain
o- = RE * .
From this, we used the propagation of standard deviations
aTotal
we were able to determine the total standard deviation of the integral photon fluence for a given
energy range.
APPENDIX C DETERMINING ANGULAR EMISSION OF GAMMAS IN
GEANT
GEANT4.8.0 allows for particle by particle sampling, allowing us to simply set up an if statement
for how to tally gammas. The geometry was set up as such:
H
Where P is the path length taken in a photon's first step (after being created by the incident
proton) along the z axis, which is the central axis of the proton beam, and oc is the path length
taken in a photon's first step in the xy plane.
a= (x- x )2 + (Y Yo)2
/ = ZI -Zo
H= a2 + 2
Where r0 is the position where the gamma is created, and r, is the position of the gamma after it's
first step. Therefore
cos(0)=AH
cos(0) z -Z 0
j(x - x0 ) + (Y - 0 )2 +1 Z 0 )2
An if statement was written that tallied the cosine of each gamma produced (with respect to the
central axis of the proton beam) provided it was created in the phantom and was created by the
primary beam.
APPENDIX D SAMPLE MCNPX INPUTS
INPUT USED TO DETERMINE THE ANGULAR DISTRIBUTION OF
THE GAMMAS EXITING THE LUCITE QA PHANTOM,
EP=147.5MEV
Cells
1 -1.19 1 -2 -100 imp:p=l imp:n,H,e=l
0 2 -3 -100 imp:p=0 imp:n,H,e=l
1 -1.19 3 -4 -100 imp:p=l imp:n,H,e=l
0 4 -5 -100 imp:p=0 imp:n,H,e=l
1 -1.19 5 -6 -100 imp:p=l imp:n,H,e=l
0 6 -7 -100 imp:p=0 imp:n,H,e=l
1 -1.19 7 -8 -100 imp:p=l imp:n,H,e=l
0 8 -9 -100 imp:p=0 imp:n,H,e=l
1 -1.19 9 -10 -100 imp:p=1l imp:n,H,e=l





































imp:n,H,e=l23 1 -1.19 23
24 -25 -100 imp:p=0 imp:n,H,e=l
-1.19 25 -26 -100 imp:p=l imp:n,H,e=l
26 -27 -100 imp:p=0 imp:n,H,e=l
-1.19 27 -28 -100 imp:p=l imp:n,H,e=l
28 -29 -100 imp:p=0 imp:n,H,e=1l
-1.19 29 -30 -100 imp:p=l imp:n,H,e=1
30 -31 -100 imp:p=0 imp:n,H,e=l
-1.19 31 -32 -100 imp:p=l imp:n,H,e=l
32 -33 -100 imp:p=0 imp:n,H,e=l
-1.19 33 -34 -100 imp:p=l imp:n,H,e=l
34 -35 -100 imp:p=0 imp:n,H,e=1l
-1.19 35 -36 -100 imp:p=l imp:n,H,e=l
36 -37 -100 imp:p=0 imp:n,H,e=l
-1.19 11 -12 -100 imp:p=l
12 -13 -100 imp:p=0 imp:n,
-1.19 13 -14 -100 imp:p=l
14 -15 -100 imp:p=0 imp:n,
-1.19 15 -16 -100 imp:p=l
16 -17 -100 imp:p=0 imp:n,
-1.19 17 -18 -100 imp:p=l
18 -19 -100 imp:p=0 imp:n,
-1.19 19 -20 -100 imp:p=1l
20 -21 -100 imp:p=0 imp:n,
-1.19 21 -22 -100 imp:p=l














37 1 -1.19 37 -38 -100 imp:p=l imp:n,H,e=l
38 0 38 -39 -100 imp:p=0 imp:n,H,e=l
39 1 -1.19 39 -40 -100 imp:p=l imp:n,H,e=l
40 0 40 -41 -100 imp:p=0 imp:n,H,e=l
41 1 -1.19 41 -42 -100 imp:p=l imp:n,H,e=l
42 0 42 -43 -100 imp:p=0 imp:n,H,e=l
43 1 -1.19 43 -44 -100 imp:p=l imp:n,H,e=l
C
100 0 (-1:44:100) -999 imp:n,H,p,e=l
C






















































mode n H p e
phys:H 150 0 -1 J 0 J 1
phys:e 100 1 1 1 1 0 0 0 0 0
phys:p 100 1 0 -1 1 0
sdef par=9 erg=147.5 pos=0 0 -.001 vec=0 0 1 dir=1
ml 1001 0.041959 6012 0.625017 8016 0.333024 $Lucite,
rho=1.190g/cc
fl:p (1 2) (3 4) (5 6) (7 8) (9 10) (11 12) (13 14) (15 16)
(17 18)
(19 20) (21 22) (23 24) (25 26) (27 28) (29 30) (31 32)
(33 34)
(35 36) (37 38) (39 40) (41 42) (43 44) $ Tally
ftl frv 0 0 1 $ cosine taken WRT vector (0,0,1)
*cl 175 35i 0 $ cosine bin from 0-180deg w/ 5 deg increments
fll:p 100
ftll frv 0 0 1
*cll 175 35i 0
fsll -1 -2 -3 -4 -5 -6 -7 -8 -9 -10 -11 -12 -13 -14 -15 -16 -
17 -18
-19 -20 -21 -22 -23 -24 -25 -26 -27 -28 -29 -30 -31 -32 -
33 -34 -35
-36 -37 -38 -39 -40 -41 -42 -43 -44
f6:H 1 3 5 7 9 11 13 15 17 19 21 23 25 27 29 31 33 35 37 39 41
43
e6 0 25 50 75 100 125 150
nps 1000000
print









































-1.19 301 -302 -601
-1.19 302 -303 -601
-1.19 303 -304 -601
-1.19 304 -305 -601
-1.19 305 -306 -601
-1.19 306 -307 -601
-1.19 307 -308 -601
-1.19 308 -309 -601
-1.19 309 -310 -601
-1.19 310 -311 -601
-1.19 311 -312 -601
-1.19 312 -313 -601
-1.19 313 -314 -601
-1.19 314 -315 -601
-1.19 315 -316 -601
-1.19 316 -317 -601
-1.19 317 -318 -601
-1.19 318 -319 -601
-1.19 319 -320 -601
-1.19 320 -321 -601
-1.19 321 -322 -601
-1.19 322 -323 -601
-1.19 323 -324 -601
-1.19 324 -325 -601
-1.19 325 -326 -601
-1.19 326 -327 -601
-1.19 327 -328 -601
-1.19 328 -329 -601
-1.19 329 -330 -601
-1.19 330 -331 -601
-1.19 331 -332 -601
-1.19 332 -333 -601
-1.19 333 -334 -601
-1.19 334 -335 -601
-1.19 335 -336 -601
-1.19 336 -337 -601
-1.19 337 -338 -601
imp:p,H,e,n=l
imp:p,H,e,n=l
imp: p, H, e, n=1
imp: p, H, e, n=1
imp:p, H, e, n=1
imp:p, H, e, n=1
imp:p, H, e, n=1
imp:p, H, e, n=1
imp:p, H, e, n=l
imp:p, H, e, n=1
imp:p, H, e, n=1
imp:p, H, e, n=1
imp:p, H, e, n=1
imp:p, H, e, n=l
imp:p,H,e,n=l
imp:p, H, e, n=1
imp:p, H, e, n=1
imp:p, H, e, n=l
imp:p, H, e, n=1
imp:p, H, e, n=l
imp :p, H, e, n=l
imp:p, H, e, n=l
imp:p, H, e, n=l
imp:p, H, e, n=1
imp:p, H, e, n=1
imp:p, H, e, n=1
imp:p, H, e, n=1
imp:p, H, e, n=l
imp:p, H, e, n=1
imp:p, H, e, n=1
imp :p, H, e, n=1
imp:p, H, e, n=1
imp:p, H, e, n=1
imp:p, H, e, n=1
imp:p, H, e, n=1
imp :p, H, e, n=1
imp:p,H,e,n=
38 1 -1.19 338 -339 -601 imp:p,H,e,n=l
39 1 -1.19 339 -340 -601 imp:p,H,e,n=l
40 1 -1.19 340 -341 -601 imp:p,H,e,n=l


















































































imp :p, H, e, n=0
imp:p, H, e, n=0
imp:p, H, e, n=0
imp:p, H, e, n=0
imp: p, H, e, n=0
imp: p, H, e, n=0
imp :p, H, e, n=0
imp:p, H, e, n=0
imp:p, H, e, n=0
imp :p, H, e, n=0
imp:p, H, e, n=0
imp:p, H, e, n=0
imp:p, H, e, n=0
imp :p, H, e, n=0
imp:p, H,e,n=0
imp:p, H, e, n=0
imp:p, H, e, n=0
imp:p, H, e, n=0
imp:p, H, e, n=0



















































































































119 2 -3.667 339 -341 602 -603 imp:n,H,e=l imp:p=2
C Void Area
998 0 -999
#1 #2 #3 #4 #5 #6 #7 #8 #9 #10 #11
#12 #13 #14 #15 #16 #17 #18 #19 #20 #21
#22 #23 #24 #25 #26 #27 #28 #29 #30 #31
#32 #33 #34 #35 #36 #37 #38 #39 #40 #41
#50 #51 #52 #53 #54 #55 #56 #57 #58 #59
#60 #61 #62 #63 #64 #65 #66 #67 #68 #69
#70
#100 #101 #102 #103 #104 #105 #106 #107
#108 #109 #110 #111 #112 #113 #114 #115
#116 #117 #118 #119
imp:H,e,n=l imp:p=2







































































C CX & C/X 401-499
C CY & C/Y 501-599






C Everything Else 701-899
C Blank Line
C Blank Line
mode p H n e
phys:H 150 0 -1 J 0 J 1
phys:e 100 1 1 1 1 0 0 0 0 0
phys:p 100 1 0 -1 1 0
C
sdef par=9 erg=147.5 pos=0 0 -.01 vec=0 0 1 dir=1
ml 1001 0.041959 6012 0.625017 8016 0.333024 $Lucite,
rho=1.190g/cc
m2 11023 0.153373 53123 0.846627 $NaI, rho=3.667g/cc
C
e6 0 25 50 75 100 125 150
fc6 Dose Deposited by p+ (for DD Curve)
f6:H 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20
21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39
40 41
e4 0 29i 150
fc4 p+ fluence
f4:H 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20
21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39
40 41
e14 0 199i 20
fcl4 Gamma Fluence in NaI Detectors
fl4:p 100 101 102 103 104 105 106 107 108 109 110 111 112 113
114




INPUT USED TO SIMULATE HETEROGENEOUS PHANTOM,




1 3 -0.3 -301 302 -601 imp:p,H,e,n=l
2 3 -0.3 -302 303 -601 imp:p,H,e,n=l
3 3 -0.3 -303 304 -601 imp:p,H,e,n=l
4 3 -0.3 -304 305 -601 imp:p,H,e,n=l
5 3 -0.3 -305 306
6 3 -0.3 -306 307
7 3 -0.3 -307 308






































imp:p, H, e, n=l
imp:p, H, e, n=l




imp:p, H, e, n=l

























imp:p, H, e, n=l
imp:p, H, e, n=l
imp:p, H, e, n=l
imp:p, H, e, n=l
imp:p, H, e, n=l
imp:p, H, e, n=l
imp:p, H, e, n=l
imp:p, H, e, n=l
imp:p, H, e, n=l
imp:p, H, e, n=l
imp:p, H, e, n=l
imp:p, H, e, n=l
imp:p, H, e, n=l
imp:p, H, e, n=l
imp:p, H, e, n=l
imp:p, H, e, n=l
imp:p, H, e, n=l
imp:p, H, e, n=l
imp:p, H, e, n=l
imp:p, H, e, n=l
imp:p, H, e, n=l
imp:p, H, e, n=l
imp:p,H,e,n=l



















































































343 602 -603 imp:p,H,e,n=0
344 602 -603 imp:p,H,e,n=0
345 602 -603 imp:p,H,e,n=0
346 602 -603 imp:p,H,e,n=0
347 602 -603 imp:p,H,e,n=0
348 602 -603 imp:p,H,e,n=0

































imp:p, H, e, n=0
imp:p, H, e, n=0
imp:p, H, e, n=0
imp:p, H, e, n=0
imp:p, H, e, n=0
imp:p, H, e, n=0
imp:p, H, e, n=0
imp:p, H, e, n=0
imp :p, H, e, n=0
imp: p, H, e, n=0
imp: p, H, e, n=0
imp:p, H, e, n=0
imp: p, H, e, n=0
imp:p, H, e, n=0
C
C NaI Detectors
100 4 -3.667 -301 303
101 4 -3.667 -303 305
102 4 -3.667 -305 307
103 4 -3.667 -307 309
104 4 -3.667 -309 311
105 4 -3.667 -311 313
106 4 -3.667 -313 315
107 4 -3.667 -315 317
108 4 -3.667 -317 319
109 4 -3.667 -319 321
110 4 -3.667 -321 323
111 4 -3.667 -323 325
112 4 -3.667 -325 327
113 4 -3.667 -327 329
114 4 -3.667 -329 331
115 4 -3.667 -331 333
116 4 -3.667 -333 335
117 4 -3.667 -335 337
118 4 -3.667 -337 339






















































imp: n, H, e=l
imp: n, H, e=l
imp:n,H,e=l











imp:p, H, e, n=l





207 2 -1.82 -707 imp:p,H,e,n=1l

































































































#24 #25 #26 #27 #28 #29 #30
#31 #32 #33 #34 #35 #36 #37
#38 #39 #40 #41 imp:p,H,e,n=l
209 3 -. 3 -709 imp:p,H,e,n=l
210 3 -.3 -710 #1 #2 #3 #4 #5 #6 #7 #8 #9 #10
#11 #12 #13 #14 #15 #16 imp:p,H,e,n=l
C
998 0 #1 #2 #3 #4 #5 #6 #7 #8 #9 #10 #11 #12
#13 #14 #15 #16 #17 #18 #19 #20 #21 #22
#23 #24 #25 #26 #27 #28 #29 #30 #31 #32
#33 #34 #35 #36 #37 #38 #39 #40 #41
#50 #51 #52 #53 #54 #55 #56 #57 #58 #59
#60 #61 #62 #63 #64 #65 #66 #67 #68 #69
#100 #101 #102 #103 #104 #105 #106 #107
#108 #109 #110 #111 #112 #113 #114 #115
#116 #117 #118 #119
#201 #202 #203 #204 #205 #206 #207 #208
imp:p, H, e, n=l
























































































































C CZ & C/Z 601-699




C Everything Else 701-899
701 RPP -10.85 10.85 -8.85 -3.85 -13 13
702 RPP -13 13 -3.85 -1.55 -13 13
703 RPP 11.15 12.4 -1.55 2.45 -11.15 11.15
704 RPP -12.4 -11.15 -1.55 2.45 -11.15 11.15
705 RPP -11.15 11.15 2.45 3.65 -11.15 11.15
706 ARB 13 3.65 -13 13 3.65 13 13 8.85 -13 13 8.45 13
-13 3.65 13 -13 3.65 -13 -13 8.85 13 -13 8.85 -13
1234 1368 2457 1265 7834 5678
709 ARB 11.15 -1.55 3.25 11.15 -1.55
11.15 11.15 2.45 3.75 11.15 2.45 11.15
1.75 -1.55 3.25 1.75 -1.55 11.15
1.25 2.45 3.75 1.25 2.45 11.15
1234 5678 1537 2648 1526 3748
708 RPP -11.15 -1.65 -1.55 2.45 -11.15 3.55
707 ARB 11.15 -1.55 -16.15 11.15 -1.55 3.25
11.15 2.45 -16.15 11.15 2.45 3.75
1.75 -1.55 -16.15 1.75 -1.55 3.25
1.25 2.45 -16.15 1.25 2.45 3.75
1234 5678 1537 2648 1526 3748





mode p H n e
phys:H 150 0 -1 J 0 J 1
phys:e 100 1 1 1 1 0 0 0 0 0
phys:p 100 1 0 -1 1 0
sdef par=9 erg=147.5 pos=-6.4 0.45 11.2 vec=0 0 -1 dir=1
ml 1001 .0805 6012 .5999 8016 .3196 $ PMMA, rho=1.18 g/cc
m2 1001 .0341 6012 .3141 7014 .0184 8016 .3650
17000 .0004 20000 .2681 $ Bone Eq., rho=1.82 g/cc
m3 1001 .0846 6012 .5938 7014 .0196 8016 .1814
12000 .1119 17000 .0010 14000 .0078 $ Lung Eq., rho=0.30
g/cc
m4 11023 0.153373 53123 0.846627 $NaI, rho=3.667g/cc
C
e6 0 25 50 75 100 125 150
fc6 Dose Deposited by p+ (for DD Curve)
f6:H 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20
21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39
40 41
e4 0 29i 150
fc4 p+ fluence
f4:H 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20
21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39
40 41
e14 0 199i 20
fcl4 Gamma Fluence in NaI Detectors
fl4:p 100 101 102 103 104 105 106 107 108 109 110 111 112 113
114
115 116 117 118 119
C
nps 100000000
print
